The molecular significance of methylated  promoter in white blood cells of cancer-free females by unknown
Al-Moghrabi et al. BMC Cancer 2014, 14:830
http://www.biomedcentral.com/1471-2407/14/830RESEARCH ARTICLE Open AccessThe molecular significance of methylated BRCA1
promoter in white blood cells of cancer-free
females
Nisreen Al-Moghrabi*, Asmaa Nofel, Nujoud Al-Yousef, Safia Madkhali, Suad M Bin Amer, Ayodele Alaiya,
Zakia Shinwari, Taher Al-Tweigeri, Bedri Karakas, Asma Tulbah and Abdelilah AboussekhraAbstract
Background: BRCA1 promoter methylation has been detected in DNA from peripheral blood cells of both breast
cancer patients and cancer-free females. However, the pathological significance of this epigenetic change in white
blood cells (WBC) remains an open question. In this study, we hypothesized that if constitutional BRCA1 methylation
reflects an elevated risk for developing breast cancer (BC), WBC that harbor methylated BRCA1 in both cancer-free
females and BC patients should exhibit similar molecular changes.
Methods: BRCA1 promoter methylation was examined by methylation-specific PCR in WBC from 155 breast cancer
patients and 143 cancer-free females. The Human Breast Cancer EpiTect Methyl II Signature PCR Array and The
Human Breast Cancer RT2 Profiler™ PCR Array were used to study the methylation status and the expression profile of
several breast cancer-related genes, respectively. In addition, we used label-free MS-based technique to study protein
expression in plasma.
Results: We have shown that 14.2% of BC patients and 9.1% of cancer-free females (carriers) harbored methylated
BRCA1 promoter in their WBC. Interestingly, 66.7% of patients harbored methylated BRCA1 promoter in both WBC and
tumors. Importantly, we have shown the presence of epigenetic changes in 9 other BC-related genes in WBC of both
patients and carriers. Additionally, BRCA1 and 15 other important cancer –related genes were found to be differentially
expressed in WBC from patients and carriers as compared to controls. Furthermore, we have shown that the carriers
exhibited a unique plasma protein pattern different from those of BC patients and controls, with 10 proteins similarly
differentially expressed in patients and carriers as compared to controls.
Conclusions: The present results suggest the presence of a strong link between aberrant methylation of the BRCA1
promoter in WBC and breast cancer –related molecular changes, which indicate the potential predisposition of the
carriers for developing breast cancer. This informs the potential use of the aberrant methylation of BRCA1 promoter in
WBC as a powerful non-invasive molecular marker for detecting predisposed individuals at a very early age.
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Epigenetic is the inheritance of information on the basis of
gene expression rather than direct changes to sequence
composition [1]. Errors in epigenetic regulation, which
result in aberrant transcriptional silencing of a normally
active gene or reactivation of a normally silent gene, are
termed epimutations [2]. In human cancers, this heritable
yet non-genetic modification is a powerful mechanism re-
sponsible for the inhibition of different types of genes, in-
cluding tumor suppressor genes [3]. Epimutation that is
found in all tissues of the body could be either germline,
with evidence of inheritance, or constitutional, no evi-
dence of inheritance. While it is still controversial whether
germline epimutations occur in humans [4-6], constitu-
tional epimutation is increasingly being considered as a
mechanism for cancer predisposition.
Breast Cancer Associated gene1, BRCA1, was identified
in 1994 as the first gene associated with familial breast
cancer predisposition [7]. Since then, germline mutations
of BRCA1 have been found to be responsible for the her-
editary type of breast cancer, which accounts for about 5-
10% of all breast cancers. Individuals carrying germline
BRCA1 mutations are more likely to develop aggressive
breast tumors at an early age (<50) [8]. These tumors are
characterized by aneuploidy, high grade, poor histologic
differentiation, and the majorities are of the triple-negative
subtype, which is negative for estrogen receptor (ER),
progesterone receptor (PR) and HER2 expression [8].
Gene silencing by epigenetic mechanisms is an alternative
mechanism for BRCA1 inactivation during sporadic car-
cinogenesis [9]. Results from various studies revealed that
9-44% of sporadic breast cancer samples harbor hyper-
methylated BRCA1 promoter [9,10]. The pathological fea-
tures of these tumors are similar to those with inherited
mutated BRCA1. Indeed, both occur at an early age and
present poor histological differentiation, aneuploidy, ER
and PR negativity, as well as similarities in their global
gene expression profiles [11,12].
Lately, BRCA1 promoter methylation has been de-
tected in DNA from both white blood cells and tumor
tissues in 3 out of 7 breast cancer patients from breast-
ovarian cancer families [13]. This suggested that BRCA1
promoter methylation occurring in normal tissue of the
body is associated with the development of BRCA1-like
breast cancer [13]. Similarly, we have recently reported
BRCA1 promoter hypermethylation in WBC genomic
DNA of 2 out of 7 (28.5%) breast cancer patients, whose
tumors showed BRCA1-like characteristics [14]. Further-
more, we have shown BRCA1 methylation in WBC of 8
out of 73 (10.9%) cancer-free women. The presence of
methylated BRCA1 promoter in healthy females may re-
veal predisposition of these individuals to develop breast
cancer. Indeed, the functional equivalence between the
effect and significance of the epigenetic silencing ofBRCA1 and the inheritance of BRCA1 mutations
[15-17], has supported the notion that BRCA1 promoter
methylation may serve as a first hit, much like an inher-
ited germline mutation.
Although several studies have indicated the association
between the presence of methylated BRCA1 promoter in
WBC and the risk of developing breast cancer [18-20],
the pathological significance of methylated BRCA1 pro-
moter in WBC of cancer-free women remains still un-
clear. In the present study, we provide clear evidences
that females with methylated BRCA1 in their WBC have,
epigenetic changes, modulated gene expression profile
and changes in protein expression in plasma similar to
that seen in BRCA1-methylated breast cancer patients,
advocating the possible involvement of BRCA1 constitu-




Breast cancer: 10 ml fresh blood samples were collected
from 155 breast cancer female patients coming to the
oncology department in King Faisal Specialist Hospital
and Research Centre in Riyadh, Saudi Arabia. Paraffin
embedded breast cancer tissues were obtained from the
Department of Pathology. The age of the patients at diag-
nosis ranged from 23 to 73 years. Clinicopathological data
(age, histological grade and ER and PR status) were pro-
vided by the Department of Pathology. Control samples:
10 ml fresh blood samples were collected from 143
healthy cancer-free female volunteers with ages ranged
from 15 to 47 years. All patients and controls gave written
informed consent to participate in the study. The study
was approved by the Human Research Ethics Committee
of King Faisal Specialist Hospital and Research Centre.
Isolation of DNA and RNA from WBC
Fresh blood was collected in 2 EDTA blood collection
tubes. The tubes were centrifuged immediately at 3000
rpm for 10 min at 4°C. The WBC layers were carefully
collected and transferred into two 2 ml Eppendorf tubes,
one containing 900 mls RBC Lysis solution for subse-
quent DNA extraction using the Gentra Puregene Blood
Kit, and the other tube contained 1.2 ml RNALater solu-
tion for subsequent RNA extraction using RiboPure
Blood Kit (Ambion).
Isolation of DNA from paraffin embedded tissues
Genomic DNA was isolated from two to three 10 μM
thick paraffin sections using Puregene kit (Gentra).
Methylation specific PCR
DNA methylation was assessed by methylation-specific
PCR of sodium bisulfate treated DNA. 1 μg of genomic
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EpiTect Bisulfite Kit (Qiagen) following the manufacturer’s
recommendations. Modified DNA was amplified with
published PCR primers for BRCA1 and MGMT [9,21] that
distinguish methylated and unmethylated DNA. PCR
products were electrophoresed on 2% agarose gels and
stained with Ethidium bromide. SssI methylase treated
and untreated bisulfite modified DNA was used as positive
and negative controls, respectively. All PCR reactions were
done in replicates.
Methylation PCR array
The Human Breast Cancer EpiTect Methyl II Signature
PCR Array (Qiagen) was used to study the methylation
status of 24 different breast cancer-related genes. 1 μg of
genomic DNA isolated from WBC was used in the array
following the manufacturer protocol. Data analysis was
done using integrated Excel-based templates provided by
the manufacturer, which provide gene methylation status
as percentage unmethylated (UM) and percentage meth-
ylated (M) fraction of input DNA. M" represents the
fraction of input genomic DNA containing two or more
methylated CpG sites in the targeted region of a gene.
2.5-fold or greater change relative to controls was deter-
mined to be the threshold cut-off point for what is con-
sidered a change in gene methylation.
RT2 Profiler™ PCR array
The Human Breast Cancer RT2 Profiler™ PCR Array was
used to profile the expression of 84 different breast
cancer-related genes. 1 μg of total RNA isolated from
WBC was revers-transcribed into cDNA using the RT2
first strand kit (SABiosciences) following the manufac-
turer’s instructions, which was then used in the Array.
The Array was set following the manufacturer’s instruc-
tions and was performed according to the manufac-
turer’s protocol. Data analysis was done using online
software PCR Array Data Analysis Web Portal provided
by the manufacturer. Gene expression levels were nor-
malized against five housekeeping genes included in the
Array. Fold changes in gene expression were calculated
using the 2-ΔΔCt method by the software. 1.5-fold or
greater change was determined to be the threshold
cut-off point for what is considered a change in gene
expression.
In solution-digestion and protein identification by mass
spectrometry: LC-MSE analysis
Plasma samples from 4 breast cancer patients, 4 carriers
and 4 controls were handled and prepared similarly.
Equal amount of proteins was taken from each sample
to generate a pool of patients as one group, a pool of
carriers, and a third pool of controls. For each analysis
sample group, 200 μg complex protein mixtures wassubjected to in-solution digestion for mass spectrometry
analysis as previously described [22,23]. We have used
the 1-Dimensional Nano Acquity liquid chromatography
coupled with tandem mass spectrometry on Synapt G2
(Waters, Manchester, UK) to generate expression prote-
omics data based on quantitative protein changes be-
tween the three sample groups. The ESI- MS analysis
and instrument settings were optimized on the tune
page as previously described [22,23]. All samples were
analyzed in triplicate runs and data were acquired using
the Mass Lynx programs (version. 4.1, SCN833, Waters,
Manchester, UK) operated in resolution and positive po-
larity modes. Protein Lynx Global Server (PLGS) 2.5
(Waters, Manchester, UK) was used for all automated
data processing and database searching. The generated
peptide masses were searched against Uniprot Human
protein sequence database using the PLGS 2.5 for pro-
tein identification (Waters, UK). TransOmics Informat-
ics (Waters Corporation, UK) was used to process and
search the data. The principle of the search algorithm is
described [24]. The following criteria were used for the
search 1 missed cleavage, Max protein mass 1000 kDa,
Trypsin, Carbamidomethyl C fixed and Oxidation M
variable modifications. Normalized label-free quantifica-
tion was achieved using Progenesis QI software, (Non-
linear Dynamics (Newcastle, UK). The data was filtered
to show only statistically significantly regulated proteins
(ANOVA), (p ≤0.001) and a fold change >1.5. The data
set was subjected to unsupervised PCA analysis.
Statistical analysis
The Chi-square and Fisher’s exact tests were performed
to determine the statistical significance for the correl-
ation between BRCA1 promoter methylation and age,
and BRCA1 promoter methylation and cancer family
history. T-test was performed to determine the statistical
significance between the different groups for methylation
(Carriers vs controls, Patients vs controls and Carriers vs
patients). ANOVA test with multiple comparisons using
SAS version 9.3(SAS Institute, Cary, NC, USA) was per-
formed for confirmation. T-test was performed to deter-
mine the statistical significance between the carriers and
the patients groups for gene methylation and expression
levels. All observed differences were considered to be
significant when associated with a P value <0.05.
Results
Identification of breast cancer patients and cancer-free
females harboring methylated BRCA1 promoter in their
WBC
In order to identify breast cancer patients and cancer-
free females harboring methylated BRCA1 promoter in
their WBC, we screened 155 patients and 143 cancer-
free females using the methylation-specific PCR (MSP)
Figure 1 MSP analysis assay, (A) MSP analysis of the BRCA1 promoter region, (B) MSP analysis of the MGMT promoter region in WBC
DNA. SssI methylase-treated and -untreated bisulfite-modified DNA was used as positive (+ve) and negative (−ve) controls, respectively. BC; breast
cancer, CR; carriers and C; controls; M, methylated product; U; unmethylated product.
Table 1 Clinical characterizations of BRCA1 methylated















13 67 + +ve +ve -ve ILC G1
138 40 + +ve +ve -ve IDC G2
172 41 + +ve -ve -ve IDC G3
154 46 + +ve +ve -ve IDC G2
176 49 + -ve -ve -ve IDC G3
116 41 + -ve -ve -ve metaplastic
181 42 - +ve +ve -ve IDC G2
171 37 ND -ve -ve -ve IDC G2
52 69 - +ve +ve -ve ILC G1
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boring methylated BRCA1 promoter (Figure 1A). Interest-
ingly, 20 out of 22 were <50 years (90.9%), and only 2
were >50 years (9.1%) (Table 1). This indicates a strong
association between the presence of methylated BRCA1
promoter in WBC and early onset of breast cancer (p =
0.032). In addition, we identified 13 cancer-free healthy
females (9.1%) harboring methylated BRCA1 promoter
in their WBC (Figure 1A). Importantly, 11 out the 13
were <40 years (84.6%), and only 2 were >40 years (15.4%)
(Table 2). Additionally, we have found a significant associ-
ation between the incidence of cancer in the family of
those subjects and the presence of BRCA1 promoter
methylation in their WBC (10/13) 77% (p = 0.036). 7 of
those families 7/10 (70%) have breast/ and or ovarian can-
cer history. For simplification, we termed cancer-free fe-
males harboring methylated BRCA1 as “Carriers”.81 27 - +ve -ve +ve IDC G2
130 39 + -ve -ve -ve IDC G3
60 40 + -ve -ve -ve IDC G2
183 36 + -ve -ve -ve IDC G2
111 44 ND +ve +ve -ve IDC G2
161 48 ND +ve +ve -ve IDC G2
187 33 ND -ve -ve -ve IDC G3
54 40 - +ve +ve -ve ILC




S3 40 - +ve +ve -ve ILC
S2 43 ND ND ND ND
F2S2 39 ND ND ND ND
IDC; Invasive ductal carcinoma.
ILC; Invasive lobular carcinoma.
ND; No data.Strong correlation between BRCA1 methylation in WBC
and matched breast tumors
Next, we sought to study the correlation between BRCA1
promoter methylation in WBC and their paired tumors.
To this end, the methylation status of the BRCA1 pro-
moter was studied, by the MSP assay, in genomic DNA
isolated from matched tumor samples obtained from the
above BRCA1 methylated positive breast cancer cases.
Out of the 22 BRCA1 methylated positive cases, only 19
archived tumor tissues were available for BRCA1 methyla-
tion analysis. The BRCA1 promoter was hypermethylated
in 10 samples, unmethylated in 5 samples and no results
could be determined for 4 samples (Table 1). This indi-
cates that 66.7% (10/15) of patients harbored methylated
BRCA1 promoter in both WBC and tumors, which reveals
strong correlation between the presences of methylated
BRCA1 promoter in WBC and matched tumor tissues.
Table 2 Cancer family history of the carriers
Carriers Samples (CR) Age Affected family members Type of cancer in affected relative BRCA1 methylation in affected
family member
CR7 25 Cousin Breast cancer ND
CR9 48 Grandmother, two aunts and cousin Breast cancer
CR18 41 Aunt (mother side) Ovarian cancer ND
CR21 17 Mother Breast cancer Yes
CR25 27 Aunt Breast cancer ND
CRF2D3 15 (Twin) Mother and two aunts (mother side) Breast cancer One aunt
CR39 22 Great grandmother (mother side) Breast cancer ND
Mother Ovarian cancer ND
CR5 28 ND Cancer (other than breast and ovarian) ND
CR10 27 No cancer in the family
CR11 26 ND Cancer (other than breast and ovarian) ND
CR17 26 No cancer in the family
CR35 22 ND Cancer (other than breast and ovarian) ND
CR59 27 NO cancer in the family
ND; No data.
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type (50%).
WBC with methylated BRCA1 show similar epigenetic
changes in both breast cancer cases and carriers
Since BRCA1 has been found to be methylated in WBC
genomic DNA, we hypothesized that other breast cancer
related genes may also be epigenetically affected. Hence,
we made use of the Human Breast Cancer EpiTect Methyl
II Signature PCR Array, which profiles the promoter
methylation status of 24 genes, whose hypermethylation is
known to play a role in breast carcinogenesis. WBC from
17 cases, 13 carriers and 10 controls were used in these
experiments. On the basis of a cut-off value of +2.5 fold
relative to controls, 9 different breast cancer-related genes,
other than BRCA1, were highly methylated in the breast
cancer cases compared to controls (Figure 2), HIC1 (p =
0.093), CDH13 (p = 0.014), CDH1 (p = 0.011), CDKN2A
(p = 0.167), MGMT (p = 0.067), SLIT2 (p = 0.013), CCNA1
(p = 0.075), TNFRSF10C (p = 0.029) and PYCARD (p =
0.269). Interestingly, the same genes, except SLIT2, were
also highly methylated in the carriers compared to
controls (Figure 2), HIC1 (p = 0.02), CDH13 (p = 0.01),
CDH1 (p = 0.025), CDKNA2 (p = 0.002), MGMT (p =
0.002), CCNA1 (p = 0.037), TNFRSF10C (p = 0.005) and
PYCARD (p = 0.02). This indicates that WBC harboring
BRCA1 promoter methylation exhibit similar epigenetic
changes in both breast cancer patients and cancer-free fe-
males. On the other hand, WBC from 5 breast cancer
cases and 4 carriers did not show any changes in methy-
lation levels for the 9 genes as compared to controls
(Figure 2A).In order to validate the signature PCR Array data, the
methylation status of MGMT was analyzed by MSP in
five control samples, two breast cancer cases, and two
carriers. The MGMT methylated band was detected in
WBC of all breast cancer cases and carrier samples.
However, only one control sample showed the presence
of a methylated MGMT band (Figure 1B).
Similar gene expression pattern in WBC with methylated
BRCA1 from breast cancer cases and carriers
Next, we sought to assess the expression of cancer-
related genes, including BRCA1, at the mRNA level, in
the WBC that harbor methylated BRCA1 promoter. To
this end, we made use of the Human Breast Cancer RT2
Profiler™ PCR Array that profiles the expression of 84
key genes, commonly involved in breast carcinogenesis,
using RNA isolated from WBC of 8 breast cancer cases,
9 carriers and 5 controls. Out of 84 genes present in the
array, 17 were not detected in the WBC. Importantly,
we have found a strong correlation between the expres-
sion level of BRCA1 in breast cancer cases and its
methylation levels detected by the Methyl II Signature
PCR Array (Figure 3A). However, only 4 samples from the
carriers group showed such correlation, CR10, CR11,
CR18 and CR25 (Figure 3B). On the basis of the cut-off
value ±1.5 fold relative to controls, 16 genes, including
BRCA1, were differentially expressed in breast cancer
cases and carriers as compared to controls (Figure 4A).
Interestingly, no significant differences were detected be-
tween the breast cancer cases and the carriers for the ex-
pression of 11 different genes:, ADAM23 (p = 0.343),
BCL2 (0.213), EGF (p = 0.90), CDKN1A (p = 0.567), CTSD
Figure 2 WBC with methylated BRCA1 show similar epigenetic changes in both breast cancer cases and carriers (A) a heat map
comparing the methylation status of a panel of 10 cancer-related genes in WBC from controls C, breast cancer BC, and carriers CR as
determined using Human Breast Cancer EpiTect Methyl II Signature PCR Array. The red color represents values of +2.5 fold relative to
controls (B) Comparison between quantitative analysis of methylation for the candidate genes in the studied cohort; Controls (n = 10), Breast
cancer (n = 17) and Carriers (n = 9). Significant correlation; Chi square. Numbers represent p values. Error bars represent the mean ± SD.
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0.165), MMP9 (p = 0.463), TGFB1 (p = 0.084) and TP53
(p = 0.334) (Figure 4B). This indicates that WBC from
cancer-free females with methylated BRCA1 has abnormal
gene expression profile similar to that seen in WBC from
breast cancer cases. On the other hand, 5 genes were dif-
ferentially expressed with significant difference between
the breast cancer patients and carriers, BRCA1 (p = 0.03),
BIRC5 (p = 0.035), CCND2 (p0.034), ATM (p = 0.012) and
IGF1R (p = 0.025) (Figure 4B).
Similar changes in protein expression pattern in plasma
from patients and carriers with WBC harboring
methylated BRCA1
It is anticipated that combination of different analyses
platforms would give better and more reliable information
to answer complex biological questions. Hence, we sought
to investigate the protein plasma signature in the carriersgroup and compare it with those from breast cancer cases
and controls. To this end, we have used the label-free MS-
based technique as a tool for quantitative and comparative
expression analysis. Approximately 400–450 proteins were
identified during each run across all sample groups. This
resulted in 91 unique protein species from all three sample
groups. Only 35 of these proteins were found to be differ-
entially expressed with significant expression changes of at
least 1.5 fold and with a probability of ≥0.95-1, between
patient, carrier and control sample groups. This dataset
discriminated the samples into three distinct groups by
unsupervised principal component analysis (PCA) and
Hierarchical Cluster Analysis (Figure 5A, B). This indi-
cates that the carriers group exhibits a unique plasma pro-
tein pattern different from those of breast cancer patients
and controls. Importantly, 10 out of the 35 differentially
expressed proteins showed similar expression patterns in
patients and carriers as compared to controls (Figure 5C).
Figure 3 Correlations of the mRNA and methylation levels of
BRCA1. Correlation between the methylation levels of BRCA1 in WBC
determined by Human Breast Cancer EpiTect Methyl II Signature PCR
Array and the mRNA levels measured by Human Breast Cancer RT2
Profiler™ PCR Array (A) breast cancer group (B) carriers group, R2;
correlation coefficient.
Al-Moghrabi et al. BMC Cancer 2014, 14:830 Page 7 of 12
http://www.biomedcentral.com/1471-2407/14/830This indicates that cancer-free females with WBC methyl-
ated BRCA1 have abnormal plasma protein expression
profile with great similarities with that seen in plasma
from the breast cancer cases.
Discussion
Up to date, the molecular and the pathological signifi-
cance of the presence of methylated BRCA1 promoter in
WBC has not been investigated. The main aim of the
present study was to investigate, at the molecular level,
whether women with methylated BRCA1 promoter in
their WBC are indeed at an elevated risk of developing
breast cancer. We have shown that the BRCA1 promoter
is methylated in WBC of 14.2% of breast cancer patients
and that this methylation is significantly associated with
the early onset of the disease. These results are in agree-
ment with previous studies, which showed that BRCA1
epimutations were significantly enriched in woman with
early-onset breast cancer [20].
While there is significant correlation between BRCA1mu-
tation and development of breast cancer, it is still contro-
versial whether or not there is a correlation between thepresence of methylated BRCA1 promoter in WBC and
paired tumor DNA from breast cancer patients [25]. In our
study, we have shown that 10 out of 15 (66.7%) breast can-
cer patients, with methylated BRCA1 in their WBC, dis-
played BRCA1 methylation in paired tumor DNA. This
suggests that methylated BRCA1 in WBC may also trigger
the formation of breast cancer. Indeed, it has been
hypothesized that constitutional BRCA1 methylation may
constitute the “first-hit” predisposing and initiating tu-
morigenesis with morphologic features similar to those
related to BRCA1 germline mutations [19]. However, in pa-
tients with no methylated BRCA1 in paired tumour DNA,
BRCA1 promoter methylation is only specific to WBC and
does not directly contribute to breast cancer of those pa-
tients [25]. Nonetheless, the fact that we have observed
similar molecular changes, in the WBC from the two groups
of patients, suggests a strong link between aberrant methyla-
tion of BRCA1 promoter in WBC and breast carcinogenesis,
regardless of its presence or absence in breast tissue.
To further appreciate the link between BRCA1 pro-
moter methylation in WBC and breast carcinogenesis we
searched for BRCA1 methylation in WBC from cancer-
free women. Since, in our previous study, we have found a
strong association between BRCA1 promoter methylation
and young age (≤40 years) at diagnosis [14], it was crucial
to screen for methylated BRCA1 promoter in cancer-free
control cohort of young age. Interestingly, we have shown
that BRCA1promoter is methylated in WBC of 9.1%
cancer-free females. Importantly, the majority of those
carriers (84%) are <40 years, which is to the contrary of
the breast cancer cases where the majority of the patients
are >40 (91%). This might be an indication for the poten-
tial predisposition of those individuals for developing
breast cancer. Interestingly, we have found that 10/13
(77%) (p = 0.036) of the carriers have cancer family history.
Importantly, 7 of those families 7/10 (70%) have breast
and/ or ovarian cancer history.
In this study, we hypothesized that if BRCA1 methylation
in WBC reflects an elevated risk for developing breast
cancer, WBC from the carriers should exhibit molecular
changes similar, to some extent, to those described in
BRCA1-methylted WBC from breast cancer patients. In-
deed, we have shown significant epigenetic changes in 9 dif-
ferent breast cancer-related genes, other than BRCA1, in
WBC from both the carriers and breast cancer patients. All
of these genes are known to be involved in different aspects
of breast carcinogenesis, which includes tumor suppression,
HIC1 [26], CDH1 [27], CDH13 [28], CDKN2 [29], DNA re-
pair, MGMT [30], apoptosis, PYCARD [31], TNFRSF10C
[32], and cell cycle regulation, CCNA1 [33]. In addition, we
report the differential expression of another fifteen cancer-
related genes, other than BRCA1, in the WBC from the car-
riers and breast cancer patients. This is very interesting as
it has always been known that many of the “cancer-related”
Figure 4 Similar gene expression pattern in WBC with methylated BRCA1 from breast cancer cases and carriers (A) a heat map
comparing the differential expression of16 cancer-related genes in WBC RNA from breast cancer patients and carriers as compared to
controls determined by using Human Breast Cancer RT2 Profiler™ PCR Array. (B) Comparison between quantitative analysis of expression
level for the candidate genes in the studied cohort; Breast cancer (n = 8), Carriers (n = 9) against controls (n = 5). Significant correlation; Chi
square. Numbers represent p values. Error bars represent the mean ± SD.
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Figure 5 Similar changes in protein expression pattern in plasma from patients and carriers (A) Principal Component Analysis using
the 35 identified proteins with significant difference in expression between plasma samples from breast cancer patients, carrier and
controls. The accession numbers of the identified proteins are indicated in the grey color, while Blue, cancer, Purple, carrier, and Orange, control.
(B) Hierarchical Cluster Analysis using the expression profiles of the 35 identified proteins with significant difference between plasma samples
from breast cancer patients, carrier and controls. (Blue, cancer, Purple, carrier, and Orange, control). (C) Histograms showing relative expression
(quantitation), based on intensities, of10 out of the 35 differentially expressed proteins (The expression changes/ abundance ratio were calculated
based on the averaged intensities of all identified peptides corresponding to an identification of a particular protein). (The proteins were
identified by LC/MS/MS/Synapt G2 and the expression data was generated using Progenesis LC-MS/QI by Nonlinear Dynamics)”. The numbers on
the x axis represent Normalized Averaged Intensities.
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WBC analyses. Nevertheless, our results demonstrate the
potential use of the WBC as an important source for profil-
ing cancer-related gene expression.
In order to validate our results, we first assessed the
methylation status and the expression level of BRCA1 in
WBC from the two studied groups. As expected, the level
of BRCA1 methylation was significantly higher in WBC
from breast cancer group than from the carriers. This was
further confirmed by showing that the BRCA1 mRNA was
significantly lower in the breast cancer group than in the
carriers. This is in concordance with the fact that constitu-
tional methylation is mono allelic [25], hence only one al-
lele of the BRCA1 gene is methylated in the carriers,
however, in the breast cancer patients, the two alleles are
affected (according to Knudsen’s hypothesis of tumor
suppressor deactivation) [34].
One of the important genes that we have shown to be
differentially expressed in the WBC from the carriers and
breast cancer patients is ATM, which is a risk factor for
breast cancer [35]. This gene is down- regulated in breast
tumours confirming its potential role in the development
of such tumours [35,36]. Intriguingly, we have shown a
significant increase in the mRNA level of ATM in the
WBC from the carries as compared to that in the breast
cancer cases. In fact, ATM is also up regulated in cases of
sclerosing adenosis (SA) [37], a benign proliferative disease
of the breast, which is an independent risk factor for sub-
sequent invasive ductal carcinomas [38]. This suggests
that the increase in the mRNA level of ATM in the WBC
of the carriers could be an indication for the potential pre-
disposition of those individuals for developing breast cancer.
The insulin-like growth factor receptor (IGF1R) is an-
other important gene that we have shown to be differen-
tially expressed in WBC from the carriers and breast
cancer patients. An elevation in the expression of IGF1R in
normal breast tissue is known to be associated with an in-
crease in the risk of subsequent breast cancer [39]. How-
ever, this gene is down-regulated in advanced human breast
cancer [40]. Similarly, the expression of IGF1R mRNA was
found to be down-regulated in peripheral blood cells and
stimulated monocytes from patients with advanced stages
of colorectal carcinoma (CRC) [41]. Conversely, IGF1R
mRNA was found to be up-regulated in tumour tissue andstimulated CRC monocytes from early stages revealing a
role of IGF1R in tumour initiation [41]. Importantly, we
have shown that the expression of IGF1R mRNA is up-
regulated in WBC from the carriers and down-regulated in
WBC from the breast cancer patients (p = 0.025). This gives
further evidence for the potential predisposition of the car-
riers for developing breast cancer.
To shed more light on this possible predisposition to
breast cancer, we investigated the protein plasma signature
in the carriers group and compare it to that in the breast
cancer cases and controls. We have identified 35 differen-
tially expressed proteins in plasma from the carriers,
breast cancer patients and controls. 10 out of those pro-
teins showed similar expression pattern between the car-
riers and the patients. The expression of one of these
proteins, Apolipoprotein CIII, was found to be reduced in
the plasma from pancreatic cancer patients as compared
to controls making it a potential marker for the early de-
tection of this disease [42,43]. Intriguingly, we have shown
here that the expression of Apolipoprotein CIII is down
regulated more than 3 fold in plasma from breast cancer
patients and about 1.5 fold in plasma from the carriers as
compared to its level in the controls plasma. This provides
another evidence for the potential predisposition of the
carriers for developing breast cancer.Conclusions
We have shown her that healthy women with BRCA1
methylation in their WBC have, besides BRCA1 methyla-
tion, modulation in the methylation and expression of
other breast cancer-related genes, in addition to the secre-
tion of important cancer- related proteins. We propose
the presence of a strong correlation between aberrant
methylation of BRCA1 promoter in WBC, regardless of its
presence or absence in breast tissue, and breast cancer-
related molecular changes, which may advocates the risk
for developing breast cancer. Our findings, together with
previous study [19], strongly suggest the potential use of
BRCA1 methylation as a powerful biomarker for detecting
predisposed women at a far early age.Competing interests
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